Semax is perhaps the most pharmacologically interesting nootropic peptide in current research. Developed in Russia and studied primarily for neuroprotective and cognitive applications, its mechanism of action involves BDNF and NGF upregulation in key brain regions — a finding with significant implications for neuroscience research.
Semax is a synthetic heptapeptide based on the ACTH(4-10) fragment — the portion of adrenocorticotropic hormone responsible for its CNS effects rather than its adrenal effects. The sequence MEHFPGP is extended at the C-terminus with Pro-Gly-Pro, a modification that dramatically improves stability against peptidase degradation and enhances CNS penetration.
Developed at the Institute of Molecular Genetics in Moscow, Semax was originally investigated for stroke treatment and cognitive impairment. It was registered as a pharmaceutical drug in Russia in 1994 and has been used clinically for neuroprotection and cognitive enhancement, providing a substantial body of human safety data alongside the preclinical research.
Brain-derived neurotrophic factor (BDNF) is arguably the most important neurotrophin in the adult brain. It promotes neuronal survival, supports synaptic plasticity (the cellular basis of learning and memory), and stimulates neurogenesis in the hippocampus — the brain region most critical for memory formation. BDNF levels decline with aging, chronic stress, and in various neurological conditions, and low BDNF is associated with cognitive decline and depression.
Research has demonstrated that Semax administration produces significant BDNF upregulation in hippocampal and cortical tissue within hours of administration. This effect appears to occur through activation of BDNF gene transcription rather than simply preventing BDNF degradation, making it a true neurotrophin-inducing mechanism rather than a protective one.
Alongside BDNF, Semax upregulates nerve growth factor (NGF) — a neurotrophin particularly important for cholinergic neuron survival and the maintenance of the basal forebrain cholinergic system that is critical for attention and memory. NGF levels were elevated 3.2-fold versus control in some hippocampal studies, a substantial effect that may have implications for research into age-related cognitive decline and cholinergic dysfunction.
Beyond neurotrophin upregulation, Semax demonstrates modulatory effects on dopaminergic and serotonergic neurotransmitter systems. Research shows measurable increases in dopamine turnover in prefrontal cortical regions, consistent with enhanced attention and executive function. Serotonin turnover is also upregulated, which may contribute to the anxiolytic and mood-stabilising effects observed in some studies.
These neurotransmitter effects appear to occur independently of the neurotrophin mechanism, suggesting Semax operates through multiple parallel pathways in the CNS rather than through a single primary mechanism.
The neuroprotective potential of Semax has been studied in ischaemia models. In rodent middle cerebral artery occlusion (MCAO) models — the standard preclinical model for ischaemic stroke — Semax administration reduced infarct volume and improved functional recovery. This neuroprotection is believed to result from a combination of BDNF upregulation (promoting neuronal survival), anti-inflammatory effects, and improved microcirculation in the penumbral zone.
Semax dissolves cleanly at up to 10 mg/mL in sterile water or saline. Given that it is a relatively small peptide (813.9 Da), it has good aqueous solubility without requiring acidic solvents. Our supplied Semax achieves 99.8% purity and is stable for up to 30 days at 4°C post-reconstitution. At 30mg per vial, it provides excellent value for extended CNS research protocols.